Peptides: The Science, Uses & Safety | Dr. Abud Bakri
BPC-157, a 15-amino-acid peptide isolated from gastric juices, shows remarkable tissue repair effects in animal studies—accelerating tendon, nerve, and gut healing. While athletes have used it for injury recovery and it's shown promise for ulcerative colitis, the science is murky: we don't know its
2h 48mKey Takeaway
BPC-157, a 15-amino-acid peptide isolated from gastric juices, shows remarkable tissue repair effects in animal studies—accelerating tendon, nerve, and gut healing. While athletes have used it for injury recovery and it's shown promise for ulcerative colitis, the science is murky: we don't know its receptor, its LD50, or even if oral doses reach systemic circulation. Most data comes from one Croatian research group. The regulatory landscape is messy—it's neither fully approved nor fully banned in the U.S., existing in a gray area of compounding pharmacy prescriptions. Before considering BPC-157, understand you're entering uncharted territory with minimal human safety data.
Episode Overview
Dr. Abu Bakri joins the Huberman Lab podcast to provide an encyclopedic discussion of peptides, focusing heavily on BPC-157, GLP-1 agonists, growth hormone secretagogues, and other compounds. The conversation explores the scientific history of BPC-157 from Pavlov's gastric juice experiments to modern injury recovery claims, examines the regulatory complexity surrounding these substances, and discusses both the promising animal data and the significant gaps in human safety research.
Key Insights
Peptides Are Biological Languages With or Without Known Receptors
Peptides function as one of the body's communication systems, alongside steroid hormones. They can be categorized by whether they have known receptors (like GLP-1s with strong clinical effects) or unknown/multiple receptors (like BPC-157 and TB-500). This distinction profoundly impacts their clinical predictability and safety profile.
BPC-157 Origins: From Pavlov's Dog Gastric Juices to Modern Peptide Science
BPC-157 is a 15-amino-acid fragment isolated from a larger 40,000-dalton protein found in gastric juices. The Croatian research group that identified it in the 1990s built on century-old observations that gastric secretions had healing properties. The original therapeutic target was gastrointestinal protection, not musculoskeletal repair—bodybuilder interest came later after animal studies showed accelerated Achilles tendon healing.
Impressive Animal Data, Minimal Human Evidence
BPC-157 has shown remarkable effects in animal models: accelerated tendon and nerve repair, protection against gastric ulcers during burn injuries, reduced alcohol intoxication and withdrawal symptoms, and survival at 1,000x normal doses without adverse effects. However, human data consists of only two small phase 1 and 2 trials using rectal enemas for ulcerative colitis—with abstracts only, no full publications. We don't even know BPC-157's LD50 (lethal dose for 50% of subjects).
The Systemic vs. Local Action Mystery
When BPC-157 is administered orally or rectally, it doesn't appear in systemic circulation—suggesting it acts locally on gut tissues or is rapidly broken down. Injectable forms presumably go systemic, but pharmacokinetics remain poorly understood. This raises fundamental questions about how it could affect tendons, nerves, and brain function if it doesn't reach those tissues when taken orally.
Regulatory Gray Area Creates Confusion and Risk
BPC-157 has never been FDA-approved. It was moved to the FDA's Category 2 list (do not compound) in late 2024, then removed in April 2025 but not yet added to Category 1 (okay to compound). Compounding pharmacies now sell "pentadecapeptide arginate" (PDA)—chemically identical to BPC-157. State medical boards vary wildly in enforcement, creating a confusing landscape where legality depends on location, formulation name, and individual board interpretation.
Notable Quotes
"People are now stacking their GLP-1 as their insulin sensitivity tool, their growth hormone or their GHR and their androgen modulation therapies as this trinity stack to get very fit, very healthy quickly."
"We don't naturally make BPC-157. We make BPC, the big protein. This group in Croatia in the '90s isolated the 15 amino acids from that giant peptide."
"They would sever tendons and then give them BPC through oral or injectable intraperitoneal administrations and they'd have faster healing times. They would sever ACL of the mice. They'd do burn wounds. When a patient has a burn wound in the ICU, they end up having crazy gastric ulcers, but if they were able to put BPC on topically for the mouse, they would have no gastric ulcers."
"What's so striking to me about BPC... Nerves don't like to regenerate in the central nervous system. There are data that I've seen with my own eyes that show you can accelerate healing of tendon, of ligament, of nerve pathways in animals. That's kind of weird."
"In the literature, when it comes to the animal data, they've injected animals with a thousand times the dose of BPC with no real adverse effects. We don't even know the LD50 of BPC, which makes it hard for it to become FDA approved."
Action Items
-
1
Understand Peptide Categories Before Use
Before considering any peptide therapy, categorize it: Does it have a known receptor with established clinical effects (like GLP-1 agonists), or does it lack a clear receptor mechanism (like BPC-157)? Peptides with unknown receptors carry significantly more uncertainty regarding both efficacy and safety.
-
2
Verify Regulatory Status in Your Jurisdiction
If considering BPC-157 or similar compounds, check both FDA categorization and your state medical board's specific regulations. Telehealth prescriptions must comply with the patient's location, not the prescriber's. Understand that "pentadecapeptide" formulations are chemically identical to BPC-157 despite different names.
-
3
Recognize the Evidence Limitations
Acknowledge that BPC-157 human safety data comes from only two small trials (phase 1 and 2) using rectal enemas for ulcerative colitis, with only abstracts published. All other evidence is animal-based. We don't know the LD50, long-term safety profile, or even basic pharmacokinetics in humans. Make decisions accordingly.
-
4
Consider Route of Administration Carefully
Understand that oral/rectal BPC-157 may not reach systemic circulation, while injectable forms likely do. If using for gut issues, oral might be appropriate; for systemic effects (injury recovery), injectable would theoretically be necessary—though this remains poorly studied. Local injection near injury sites is common practice but lacks robust human validation.